Eli Lilly (LLY)
(Delayed Data from NYSE)
$776.38 USD
-29.68 (-3.68%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $774.63 -1.75 (-0.23%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$776.38 USD
-29.68 (-3.68%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $774.63 -1.75 (-0.23%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
The Zacks Analyst Blog Highlights Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK
by Zacks Equity Research
Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK are included in this Analyst Blog.
5 Big Drug Stocks That May Continue to Outperform in 2024
by Kinjel Shah
Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.
Eli Lilly (LLY) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $572.04 in the latest trading session, marking a -0.28% move from the prior day.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
LLY Down as Patients Regain Weight After Stopping Zepbound
by Zacks Equity Research
Full results from a late-stage study show that patients who stopped taking Eli Lilly's (LLY) weight-loss drug for over a year slowly started to regain their lost weight.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
Eli Lilly (LLY) Rises Higher Than Market: Key Facts
by Zacks Equity Research
The latest trading day saw Eli Lilly (LLY) settling at $598.05, representing a +1.66% change from its previous close.
Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod
by Kinjel Shah
AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.
Zacks Market Edge Highlights: SAIC, ANET, LLY, PFE and SIG
by Zacks Equity Research
SAIC, ANET, LLY, PFE and SIG have been highlighted in this Market Edge article.
Will There Be a Recession in 2024?
by Tracey Ryniec
Tracey Ryniec and John Blank examine whether a recession is looming and how to invest in the new year.
Is it a Good Idea to Invest in AC Immune (ACIU) Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in AC Immune (ACIU) stock now may turn out to be a prudent move.
Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca
by Zacks Equity Research
Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.
Roche (RHHBY) to Acquire Obesity Drug Maker Carmot for $2.7B
by Zacks Equity Research
Roche (RHHBY) aims to enter the promising and much-in-demand obesity drug market with the acquisition of Carmot Therapeutics, Inc. for $2.7 billion.
Altimmune (ALT) Rises 83% on Successful Phase II Obesity Study
by Zacks Equity Research
Altimmune (ALT) reports positive top-line data from its 48-week phase II MOMENTUM study of obesity drug candidate, pemvidutide. The stock gains 83%.
Pfizer (PFE) Stock Down 5% as Obesity Drug Fails in Phase II
by Zacks Equity Research
The failure of the phase IIb study on danuglipron is a significant blow to Pfizer's (PFE) efforts to take a share of the growing market of GLP-1 drugs for treating obesity.
Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why
by Zacks Equity Research
Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $10.1 Billion
by Zacks Equity Research
AbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify its oncology pipeline across solid tumors and hematologic malignancies.
The Zacks Analyst Blog Highlights AbbVie, J&J, Eli Lilly, Pfizer
by Zacks Equity Research
AbbVie, J&J, Eli Lilly, Pfizer are included in this Analyst Blog.
Alexandria (ARE), Eli Lilly to Expand Gateway Labs to San Diego
by Zacks Equity Research
The expansion of Gateway Labs to San Diego reaffirms the strength and depth of the partnership between Alexandria (ARE) and Eli Lilly.
4 Large Drug Stocks to Watch as IBD Market Gains Traction
by Kinjel Shah
As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).
Is Invesco Large Cap Growth ETF (PWB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PWB